Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Beginning Cash Balance: 2009-2025

Historic Beginning Cash Balance for Ani Pharmaceuticals (ANIP) over the last 17 years, with Sep 2025 value amounting to $217.8 million.

  • Ani Pharmaceuticals' Beginning Cash Balance fell 9.28% to $217.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.0 million, marking a year-over-year decrease of 24.90%. This contributed to the annual value of $221.1 million for FY2024, which is 315.31% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Beginning Cash Balance is $217.8 million, which was up 45.39% from $149.8 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Beginning Cash Balance high stood at $240.1 million for Q3 2024, and its period low was $7.9 million during Q1 2021.
  • For the 3-year period, Ani Pharmaceuticals' Beginning Cash Balance averaged around $165.7 million, with its median value being $161.7 million (2023).
  • As far as peak fluctuations go, Ani Pharmaceuticals' Beginning Cash Balance crashed by 87.38% in 2021, and later skyrocketed by 1,174.96% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Beginning Cash Balance (Quarterly) stood at $15.3 million in 2021, then surged by 268.94% to $56.3 million in 2022, then soared by 243.08% to $193.1 million in 2023, then dropped by 24.91% to $145.0 million in 2024, then declined by 9.28% to $217.8 million in 2025.
  • Its last three reported values are $217.8 million in Q3 2025, $149.8 million for Q2 2025, and $144.9 million during Q1 2025.